A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
13. September 2012 aktualisiert von: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Phase 1 Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Subjects With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
The purpose of this study is to explore the safety, pharmacokinetic (what the body does to the medication), pharmacodynamic (what the medication does to the body), and activity of JNJ-26481585 in patients with advanced or refractory leukemia and myelodysplastic syndrome (MDS).
Studienübersicht
Status
Beendet
Intervention / Behandlung
Detaillierte Beschreibung
This is an open-label (all people know the identity of the intervention), Phase 1 dose escalation, 2-part study (Part I and Part II).
In Part I of the study, the Maximum Tolerated Dose (MTD) defined as the highest dose with an observed incidence of dose limiting toxicity (DLT) in no more than 1 in 6 patients, will be determined using rapid escalation (Stage 1) followed by conventional escalation (Stage 2).
In Stage 1, at least 2 patients will be enrolled at each dose level; dose increments of 100% will be applied.
In Stage 2, at least 3 patients will be enrolled at each dose level and dose increments of 20-50% will be implemented.
Decisions on dose escalation or de-escalation, changes in the timing of pharmacokinetic/pharmacodynamic sampling, and the exploration of an alternative schedule were to be made by the Study Evaluation Team (SET), which consisted of all principal investigators, the medical monitor, and 1 of the sponsor's clinical pharmacologists.
Part II of the study will be the expansion phase, which will begin after the MTD had been determined in Part I and an additional cohort of patients with MDS will be enrolled to further explore the safety and activity of JNJ 26481585 in patients with MDS.
The starting dose for patients enrolled in Part II of the study was to be the MTD established in Part I. Depending on the outcome, the SET may decide to continue at the MTD dose, or dose-de-escalate to the next lower level (25 50% decrement from MTD).
The cohort for MDS will be expanded to consist of 16 evaluable patients.
Safety will be evaluated throughout the study and will include evaluations of adverse events clinical laboratory tests, electrocardiogram (ECG), vital signs, 24 hours Holter ECG, physical examination, Eastern Cooperative Oncology Group performance status and Multiple Gated Acquisition scan or echocardiography.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
10
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten
-
-
Texas
-
Houston, Texas, Vereinigte Staaten
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Histologically or cytologically confirmed advanced or refractory acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia in blast phase, refractory chronic lymphocytic leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia
- For Part II, patients with myelodysplastic syndrome
- Eastern Cooperative Oncology Group Performance Status Score 0, 1 or 2
- Left Ventricular Ejection Fraction greater than or equal to 50%
- Negative hepatitis B, C and human immunodeficiency virus (HIV) test within last 3 months
- Adequate liver and kidney function
Exclusion Criteria:
- Known or suspected involvement of the central nervous system
- Chemotherapy (nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy or treatment with investigative agent within 3 weeks before study drug administration (except hydroxyurea which should be stopped at least 24 hours prior to first dose)
- Unstable angina or myocardial infarction within the preceding 12 months; congestive heart failure
- Poorly controlled hypertension or diabetes, ongoing active infection and psychiatric illness
- Receiving medications known to have a risk of causing QTc prolongation
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: JNJ-26481585
|
In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle.
Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of patients with adverse events
Zeitfenster: Upto 14 days after last dose administration of study medication
|
Upto 14 days after last dose administration of study medication
|
|
|
Number of patients with dose limiting toxicity [DLT]
Zeitfenster: From the date of dosing upto 3 months after the date the last patient enrolled in Part I of the study, received the first dose of study medication
|
Only toxicities that occur during Treatment Cycle 1 will be used for the purposes of defining DLT.
|
From the date of dosing upto 3 months after the date the last patient enrolled in Part I of the study, received the first dose of study medication
|
|
Maximum tolerated dose (MTD) of JNJ 26481585
Zeitfenster: From the date of dosing upto 3 months after the date the last patient enrolled in Part I of the study, received the first dose of study medication
|
The MTD is defined as the highest dose with an observed incidence of DLT in no more than 1 in 6 patients.
|
From the date of dosing upto 3 months after the date the last patient enrolled in Part I of the study, received the first dose of study medication
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum plasma concentration (Cmax) of JNJ 26481585
Zeitfenster: Days 1, 2, 8, 15 and 21 of Cycle 1
|
Days 1, 2, 8, 15 and 21 of Cycle 1
|
|
|
Time to reach maximum plasma concentration (tmax) of JNJ-26481585
Zeitfenster: Days 1, 2, 8, 15 and 21 of Cycle 1
|
Days 1, 2, 8, 15 and 21 of Cycle 1
|
|
|
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24)
Zeitfenster: Days 1, 2, 8, 15 and 21 of Cycle 1
|
Days 1, 2, 8, 15 and 21 of Cycle 1
|
|
|
Elimination half-life (t1/2) of JNJ-26481585
Zeitfenster: Days 1, 2, 8, 15 and 21 of Cycle 1
|
Days 1, 2, 8, 15 and 21 of Cycle 1
|
|
|
Cumulative amount of drug excreted in urine over 24 hours (Ae24)
Zeitfenster: Days 1 and 21 of Cycle 1
|
Days 1 and 21 of Cycle 1
|
|
|
Renal clearance (CLR) of JNJ 26395018
Zeitfenster: Days 1 and 21 of Cycle 1
|
Days 1 and 21 of Cycle 1
|
|
|
Concentration of biomarker histone acetylation
Zeitfenster: Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
|
Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
|
|
|
Concentration of biomarker interleukin-6 (IL-6)
Zeitfenster: Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
|
Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
|
|
|
Concentration of biomarker heat shock protein 90 (Hsp90)
Zeitfenster: Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
|
Days 1 and 21 of Cycle 1; Day 21 of Cycles 2 to 20
|
|
|
Complete Blood Count (CBC)
Zeitfenster: Pre-treatment (within 4 weeks prior to first dose of JNJ-26481585); Days 1, 3, 8, 15 and 21 of Cycle 1; Days 8, 15 and 21 of Cycle 2; Day 21 of Cycle 3 to 20; follow up (within 14 days after last dose of JNJ-26481585)
|
Anticancer activity of JNJ-26481585 explored by assessment of response parameters such as CBC.
|
Pre-treatment (within 4 weeks prior to first dose of JNJ-26481585); Days 1, 3, 8, 15 and 21 of Cycle 1; Days 8, 15 and 21 of Cycle 2; Day 21 of Cycle 3 to 20; follow up (within 14 days after last dose of JNJ-26481585)
|
|
Assessment of Transfusion Record
Zeitfenster: From Day 1 of Cycle 1 upto 14 days after last dose
|
Assessment of Transfusion Record is the parameter for assessment of response.
|
From Day 1 of Cycle 1 upto 14 days after last dose
|
|
Radiological Tumor Mass assessment
Zeitfenster: Pre-treatment, Day 21 of Cycle 2 to 20 and follow up
|
Radiological Tumor Mass assessment is the parameter for assessment of response.
|
Pre-treatment, Day 21 of Cycle 2 to 20 and follow up
|
|
Bone marrow aspirate/biopsy assessment
Zeitfenster: Pre-treatment, Day 21 of Cycles 1 to 20
|
Bone marrow aspirate/biopsy assessment is the parameter for assessment of response.
|
Pre-treatment, Day 21 of Cycles 1 to 20
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Dezember 2008
Primärer Abschluss (Tatsächlich)
1. September 2011
Studienabschluss (Tatsächlich)
1. September 2011
Studienanmeldedaten
Zuerst eingereicht
8. Mai 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
12. Mai 2008
Zuerst gepostet (Schätzen)
13. Mai 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
14. September 2012
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. September 2012
Zuletzt verifiziert
1. September 2012
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CR013960
- 26481585CAN1003 (Andere Kennung: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .